Millennium Management
CRSP icon

Millennium Management’s CRISPR Therapeutics CRSP Stock Holding History

Millennium Management’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-2,400
Closed -$389K – 6846
2021
Q2 		$389K Sell
2,400
-5,100
-68% -$620K ﹤0.01% 5504
2021
Q1 		$914K Buy
+7,500
New +$1.13M ﹤0.01% 4304

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Millennium Management's CRSP Position: Q2 2026 in Review

Millennium Management increased its CRISPR Therapeutics (CRSP) stake by 1.3% in Q2 2026, buying an estimated $256K and bringing the position to 382,032 shares worth $20.8M. The position accounts for 0.01% of the portfolio, ranked #1587.

Millennium Management first reported a position in CRSP in Q4 2016 and has held it in 30 quarters since. The position peaked at $29.2M in Q4 2021. 523 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Millennium Management held 382,032 shares of CRISPR Therapeutics worth $20.8M as of Q2 2026.
  • Millennium Management bought 4,854 CRISPR Therapeutics shares in Q2 2026, an estimated $256K.
  • CRISPR Therapeutics made up 0.01% of Millennium Management's portfolio in Q2 2026, its #1587 holding.
  • Millennium Management first reported a position in CRISPR Therapeutics in Q4 2016 and has held it in 30 quarters since.
  • Millennium Management's CRISPR Therapeutics position peaked at $29.2M in Q4 2021.
  • 523 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.